Literature DB >> 1490833

Color vision in Stargardt's disease.

M Mäntyjärvi1, K Tuppurainen.   

Abstract

The color vision of nine patients aged from 13 to 52 years with Stargardt's disease was studied with the following tests: Standard Pseudoisochromatic Plates part 2 (SSP2), Farnsworth-Munsell 100 hue test (FM100), Nagel (red-green) anomaloscope and Besançon (blue) anomalometer. At the beginning of the disease, a very slight defect in red-green color vision could be demonstrated. Later, a distinct acquired red (pseudo-protanomalous) defect in the Nagel anomaloscope and an abnormal error score in the FM100 test were observed. In advanced stages, the red defect became stronger (scotopization) and the FM100 test showed a red-green axis. In the course of the disease, a blue defect with the SPP2 plates and with the Besançon anomalometer could also be found. The visual acuities of the patients had a significant correlation with the matching ranges of the Rayleigh equation and the Moreland equation. The duration of the disease did not show any correlation with the color vision tests.

Entities:  

Mesh:

Year:  1992        PMID: 1490833     DOI: 10.1007/bf00918432

Source DB:  PubMed          Journal:  Int Ophthalmol        ISSN: 0165-5701            Impact factor:   2.031


  26 in total

1.  [Juvenile macular degenerescence predominantly affecting photopic vision].

Authors:  J FRANCOIS; G VERRIEST; A DE ROUCK; A HUMBLET
Journal:  Ophthalmologica       Date:  1956-06       Impact factor: 3.250

2.  Drusen and fundus flavimaculatus: clinical, functional, and histologic characteristics.

Authors:  F W Newell; A E Krill; T G Farkas
Journal:  Trans Am Acad Ophthalmol Otolaryngol       Date:  1972 Jan-Feb

3.  Stargardt's hereditary progressive macular degeneration.

Authors:  A R Irvine; F L Wergeland
Journal:  Br J Ophthalmol       Date:  1972-11       Impact factor: 4.638

4.  Color-axis determination on the Farnsworth-Munsell 100-hue test.

Authors:  V C Smith; J Pokorny; A S Pass
Journal:  Am J Ophthalmol       Date:  1985-07-15       Impact factor: 5.258

5.  A new assessment of the normal ranges of the Farnsworth-Munsell 100-hue test scores.

Authors:  G Verriest; J Van Laethem; A Uvijls
Journal:  Am J Ophthalmol       Date:  1982-05       Impact factor: 5.258

6.  Fundus flavimaculatus. Clinical, functional and histopathologic observations.

Authors:  B A Klien; A E Krill
Journal:  Am J Ophthalmol       Date:  1967-07       Impact factor: 5.258

7.  Visual acuity loss in patients with Stargardt's macular dystrophy.

Authors:  G A Fishman; M Farber; B S Patel; D J Derlacki
Journal:  Ophthalmology       Date:  1987-07       Impact factor: 12.079

8.  Retinal pigment epithelial abnormalities in fundus flavimaculatus: a light and electron microscopic study.

Authors:  R C Eagle; A C Lucier; V B Bernardino; M Yanoff
Journal:  Ophthalmology       Date:  1980-12       Impact factor: 12.079

9.  Autosomal-dominant fundus flavimaculatus. Clinicopathologic correlation.

Authors:  P F Lopez; I H Maumenee; Z de la Cruz; W R Green
Journal:  Ophthalmology       Date:  1990-06       Impact factor: 12.079

10.  [The importance of fluorescein angiography in the diagnosis of Stargardt's mascular degeneration (author's transl)].

Authors:  W Hammerstein; E Leide
Journal:  Klin Monbl Augenheilkd       Date:  1981-01       Impact factor: 0.700

View more
  5 in total

1.  Localization and functional characterization of the p.Asn965Ser (N965S) ABCA4 variant in mice reveal pathogenic mechanisms underlying Stargardt macular degeneration.

Authors:  Laurie L Molday; Daniel Wahl; Marinko V Sarunic; Robert S Molday
Journal:  Hum Mol Genet       Date:  2018-01-15       Impact factor: 6.150

Review 2.  Defective lipid transport and biosynthesis in recessive and dominant Stargardt macular degeneration.

Authors:  Robert S Molday; Kang Zhang
Journal:  Prog Lipid Res       Date:  2010-07-13       Impact factor: 16.195

3.  Three-Year Safety Results of SAR422459 (EIAV-ABCA4) Gene Therapy in Patients With ABCA4-Associated Stargardt Disease: An Open-Label Dose-Escalation Phase I/IIa Clinical Trial, Cohorts 1-5.

Authors:  Maria A Parker; Laura R Erker; Isabelle Audo; Dongseok Choi; Saddek Mohand-Said; Kastytis Sestakauskas; Patrick Benoit; Terence Appelqvist; Melissa Krahmer; Caroline Ségaut-Prévost; Brandon J Lujan; Ambar Faridi; Elvira N Chegarnov; Peter N Steinkamp; Cristy Ku; Mariana Matioli da Palma; Pierre-Olivier Barale; Sarah Ayelo-Scheer; Andreas Lauer; Tim Stout; David J Wilson; Richard G Weleber; Mark E Pennesi; José Alain Sahel; Paul Yang
Journal:  Am J Ophthalmol       Date:  2022-03-04       Impact factor: 5.488

4.  Retinal phenotypic characterization of patients with ABCA4 retinopathydue to the homozygous p.Ala1773Val mutation.

Authors:  Salvador López-Rubio; Oscar F Chacon-Camacho; Rodrigo Matsui; Dalia Guadarrama-Vallejo; Mirena C Astiazarán; Juan C Zenteno
Journal:  Mol Vis       Date:  2018-02-01       Impact factor: 2.367

5.  Correlating the Expression and Functional Activity of ABCA4 Disease Variants With the Phenotype of Patients With Stargardt Disease.

Authors:  Fabian Garces; Kailun Jiang; Laurie L Molday; Heidi Stöhr; Bernhard H Weber; Christopher J Lyons; David Maberley; Robert S Molday
Journal:  Invest Ophthalmol Vis Sci       Date:  2018-05-01       Impact factor: 4.799

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.